The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study
Open accessAbstract
Early treatment of acute hepatitis C with interferon alpha-2b for 24 weeks prevents chronic infection in almost all patients. Because pegylated interferons have replaced conventional interferon in the therapy of chronic hepatitis C, the aim of this study was to analyze the efficacy of an early treatment of acute hepatitis C with peginterferon alfa- 2b. Between February 2001 and February 2004, 89 individuals with acute HCV infection were recruited at 53 different centers in Germany. Patients received 1.5 μg/kg peginterferon alfa-2b for 24 weeks; treatment was initiated after a median of 76 days after infection (range 14-150). End-of-treatment response and sustained virological response were defined as undetectable HCV RNA at the end of therapy and after 24 weeks of follow-up, respectively. In the total study population, virological response was 82% at the end of treatment and 71% at the end of follow-up. Of 89 individuals, 65 (73%) were adherent to therapy, receiving 80% of the interferon dosage within 80% of the scheduled treatment duration. End-of-treatment and sustained virological response rates in this subpopulation were 94% and 89%, respectively. A maximum alanine aminotransferase level of more than 500 U/L prior to therapy was the only factor associated with successful treatment. In conclusion , in acute HCV infection, early treatment with peginterferon α2b leads to high virological response rates in individuals who are adherent to treatment. The high number of dropouts underlines the importance of thorough patient selection and close monitoring during therapy. Thus, future studies should identify factors predicting spontaneous viral clearance to avoid unnecessary therapy. (Hepatology 2006;43:250–256.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Natural History of Community-Acquired Hepatitis C in the United States
Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272702 · Cited by 1,592
Cited by
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.023 · Cited by 1,088
Treating viral hepatitis C: efficacy, side effects, and complications
Manns, M. P., Wedemeyer, H., & Cornberg, M. (2006) · Gut · doi:10.1136/gut.2005.076646 · Cited by 659
Self-citationManns, M. P., Buti, M., Gane, E., Pawlotsky, J.-M., Razavi, H., Terrault, N., & Younossi, Z. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.6 · Cited by 506
Self-citationPeginterferon and Ribavirin for Chronic Hepatitis C
Hoofnagle, J. H., & Seeff, L. B. (2006) · New England Journal of Medicine · doi:10.1056/nejmct061675 · Cited by 476
Webster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
Metadata
- Authors
- Wiegand, J., Buggisch, P., Boecher, W., Zeuzem, S., Gelbmann, C. M., Berg, T., Kauffmann, W., Kallinowski, B., Cornberg, M., Jaeckel, E., Wedemeyer, H., & Manns, M. P.
- Venue
- Hepatology
- Published
- 2006-02
- Volume
- 43
- Issue
- 2
- Pages
- 250-256
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2154628753
- Cited by
- 250
- References
- 1
- FWCI
- 20.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.